BCM
CPIX icon

BlueCrest Capital Management’s Cumberland Pharmaceuticals CPIX Stock Holding History

BlueCrest Capital Management’s Portfolio CPIX Stock Details CPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-10,906
Closed -$63K – 541
2019
Q1 		$63K Buy
+10,906
New +$63.3K ﹤0.01% 1119

Other funds holding CPIX

AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

BlueCrest Capital Management's CPIX Position: Q2 2019 in Review

BlueCrest Capital Management sold out of Cumberland Pharmaceuticals (CPIX) in Q2 2019, closing a stake of 10,906 shares — an estimated $63K sold.

BlueCrest Capital Management first reported a position in CPIX in Q1 2019 and held it in 1 quarter. The position peaked at $63K in Q1 2019. 24 funds tracked by Wall St. Rank hold CPIX as of Q2 2019.

  • BlueCrest Capital Management reported no remaining Cumberland Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 10,906 Cumberland Pharmaceuticals shares in Q2 2019, an estimated $63K.
  • BlueCrest Capital Management first reported a position in Cumberland Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • BlueCrest Capital Management's Cumberland Pharmaceuticals position peaked at $63K in Q1 2019.
  • 24 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q2 2019.

Based on BlueCrest Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.